LRMR
NASDAQ · Biotechnology
Larimar Therapeutics Inc
$4.13
+0.04 (+0.98%)
Open$4.08
Previous Close$4.09
Day High$4.21
Day Low$4.04
52W High$6.42
52W Low$1.73
Volume—
Avg Volume1.90M
Market Cap371.90M
P/E Ratio—
EPS$-2.21
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+463.4% upside
Current
$4.13
$4.13
Target
$23.27
$23.27
$16.60
$23.27 avg
$30.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 175.11M | 171.92M | 184.32M |
| Net Income | -19,494,630 | -18,016,562 | -21,970,966 |
| Profit Margin | -11.1% | -10.5% | -11.9% |
| EBITDA | -28,814,403 | -28,168,357 | -29,490,113 |
| Free Cash Flow | -20,989,250 | -18,411,143 | -19,560,158 |
| Rev Growth | -5.1% | +17.2% | +14.9% |
| Debt/Equity | 0.69 | 0.58 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |